About CARDIOPHARMAGENET
Learn more about CardioPharmaGENET, a pan-European network dedicated to advancing cardiovascular care through pharmacogenomics and personalized medicine. The project brings together researchers, clinicians, and policymakers to drive innovation, collaboration, and the integration of genetic insights into clinical practice.
Network for Cardiovascular Pharmacogenomics and Precision Medicine
CardioPharmaGENET is a pan-European research and innovation network dedicated to advancing personalized medicine in cardiovascular care through the application of pharmacogenomics (PGx). Pharmacogenomics investigates how genetic variability influences individual responses to drug therapies, which is particularly relevant in cardiovascular medicine due to substantial inter-individual differences in drug efficacy and safety.
The primary objective of the Action is to establish a multidisciplinary and inclusive European network that bridges the gap between pharmacogenomic research and clinical implementation. By integrating expertise from biomedical research, clinical practice, bioinformatics, and policy development, the initiative aims to optimize cardiovascular therapies and improve patient outcomes across diverse populations.
CardioPharmaGENET addresses several critical barriers that currently limit the effective use of PGx in cardiovascular healthcare. These include insufficient disease-specific pharmacogenomic evidence, lack of centralized and accessible knowledge resources, limited integration of PGx into routine clinical workflows, underutilization of artificial intelligence (AI) for genomic data analysis, fragmented regulatory frameworks across European countries, and limited international collaboration and knowledge exchange.
To systematically tackle these challenges, the Action is structured into five interconnected Working Groups (WGs)
1.
Working Group 1
Current Landscape and Status of PGx in Cardiovascular Medicine
2.
Working Group 2
Pharmacogenetic Guideline Development and Optimization
3.
Working Group 3
AI/ML Use in PGx of Cardiovascular Medicine
4.
Working Group 4
Policy Regulation and Impact Analysis Across Europe
5.
Working Group 5
Communication, Dissemination and Exploitation
Network for Cardiovascular Pharmacogenomics and Precision Medicine
A central outcome of CardioPharmaGENET is the development of a comprehensive, centralized knowledge hub that consolidates pharmacogenomic data, clinical guidelines, and best practices. This resource is intended to support clinicians, researchers, and policymakers in making informed, data-driven decisions and to promote standardized implementation of PGx across healthcare systems.
In parallel, the Action emphasizes capacity building through structured training activities, including workshops, training schools, webinars, and short-term scientific missions. These initiatives aim to enhance the competencies of healthcare professionals and researchers, facilitating the integration of pharmacogenomics into clinical practice.
CardioPharmaGENET also prioritizes the development of robust digital infrastructure and AI-driven tools that comply with European regulatory standards, enabling efficient and ethical use of genomic data in clinical decision-making. By fostering collaboration with established international initiatives and consortia, CardioPharmaGENET contributes to the harmonization of methodologies and policies at a global level.
Through its coordinated and multidisciplinary approach, CardioPharmaGENET supports the equitable implementation of pharmacogenomics in cardiovascular care, reduces disparities in access to personalized therapies, and promotes evidence-based, patient-centered treatment strategies across Europe.